The incidence of pancreatic ductal adenocarcinoma (PDAC) nearly equals its mortality rate, partly because most PDACs are intrinsically chemoresistant and thus largely untreatable. It was found recently that chemoresistant PDAC cells overexpress the Notch-2 receptor and have undergone epithelial-mesenchymal transition (EMT). In this study, we show that these two phenotypes are interrelated by expression of Midkine, a heparin binding growth factor that is widely overexpressed in chemoresistant PDAC. Gemcitabine, the front line chemotherapy used in PDAC treatment, induced Midkine expression in a dose-dependent manner and its RNAi-mediated depletion was associated with sensitization to gemcitabine treatment. We identified an interaction between the Notch-2 receptor and Midkine in PDAC cells. Midkine-Notch-2 interaction activated Notch signaling, induced EMT, upregulated NF-κB and increased chemoresistance. Taken together, our findings define an important pathway of chemoresistance in PDAC and suggest novel strategies for its clinical attack.
Introduction
Insufficient diagnostic tools and therapeutic options for pancreatic ductal adenocarcinoma (PDAC) still substantiate its ranking as 4 th leading cause of cancer related death (1) . The combination of an unusual aggressiveness and early metastatic locoregional as well as distant spread reflects the urgent necessity of new therapeutic options for this deadly disease since its incidence nearly equals mortality. This devastating prognosis is partially due to a frequent occurrence of intrinsic or acquired chemoresistance in PDAC specimens against the nucleoside analogue gemcitabine which is still the standard for chemotherapeutic treatment of locally advanced and metastatic PDAC (2) .
The heparin binding growth-factor Midkine (MK) was first identified as a retinoic-acid inducible gene during embryogenesis two decades ago (3) . Since then a plethora of cellular MK functions have been described in normal and transformed tissue. While MK geneexpression is weak or undetectable in adults, the MK re-expression in damaged and inflamed
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Fibronectin and α-smooth-muscle-actin (α-SMA) (10) (11) (12) . EMT is triggered by a tightly regulated interplay of extracellular signals such as soluble growth-factors like epidermal growth-factor or transforming growth-factor ß (13) (14) . Numerous receptors such as Notch have been identified playing a significant role in the acquisition of EMT in cancer (15) . The activation of Notch regulates expression of target genes playing important roles in embryonic development, cell proliferation and apoptosis. Recently, the activated Notch receptor-2 (Notch-2) was shown to mediate an EMT phenotype in PDAC cells whereas chemotherapy (oxaliplatin) -induced Notch-1 activation was shown to be linked to acquired chemoresistance in colon cancer cells (16) . Moreover, Notch-2 was recently shown to interact with MK to regulate cell plasticity and motility in human keratinocytes (17) .
Materials and Methods
Cell lines. Tumor-tissues for establishment of primary chemoresistant PDAC cell lines (PaCa 5061, 5072, 5156) were taken from patients who underwent total pancreaticoduodenectomy for advanced PDAC in the Surgery, University Medical Center Hamburg (2009). Written informed consent of patients was obtained prior to surgery. The procedure of cell line establishment from tumor-tissue was previously published (18) . Primary cells were cultured in TUM medium. L3.6pl (19) Midkine was amplified by PCR and subcloned for expression into pCS2 (20) .
Immunoprecipitation (IP) and Western blotting. PANC-1 cells were transfected with indicated plasmids. Following transfection, cells were lysed in RIPA buffer (Sigma) containing 1x protease inhibitor cocktail (Roche). Supernatants were resolved by SDS-PAGE followed by immunoblotting or immunoprecipitation as previously described (20) . Western blots, IPs and immunostainings were performed using antibodies listed in supplementary 
Results
Midkine is frequently overexpressed in chemoresistant PDAC. The PDAC cell line PaCa 5061 has recently been characterized in-depth in vitro and in vivo (18) . To identify novel players involved in intrinsic or acquired chemoresistance in PDAC, we analyzed the geneexpression profile of three newly established chemoresistant cell lines (PaCa 5061, 5072, 5156) in comparison to RNA expression patterns obtained from two independent normal pancreas specimens. The native intrinsic gemcitabine-resistance was examined in all lines prior to the analysis. To identify chemoresistance-relevant molecules we searched for "hits" over-represented more than 5-fold in all resistant lines compared to normal pancreas. Among the top 5 hits we identified MK as overexpressed in cell lines (Fig. 1A, left) . The P values and fold changes of selected genes are shown in Table 1 (Supplementary Table S1 ). To further validate our microarray results, we re-tested MK-overexpression and performed realtime RT-PCR to quantify MK mRNA in the investigated lines (Fig. 1A, right) . We expanded these analyses and quantified MK mRNA-expression in more than 30 additional PDAC tissues by real-time RT-PCR (Fig. 1B) . We observed a statistically significant mRNAoverexpression in more than 50% of the investigated samples (P<0.05). To verify that the MK mRNA-expression resulted in robust protein-expression, we performed immunostainings from same tissues or investigated MK protein-expression in cell lines and showed that mRNA-overexpression resulted in robust protein-expression. Consistent with previous role in chemoresistance. To test this, we treated chemosensitive and chemoresistant lines with gemcitabine. Interestingly, we found that MK protein-levels were increased in a dosedependent manner in chemoresistant cells ( Fig. 2A, top) . In contrast, treatment of chemosensitive cells failed to increase MK protein-levels ( Fig. 2A, bottom) . Moreover, MK protein-levels were only barely detectable in control-treated as well as gemcitabine-treated chemosensitive cells. As it is known that the MK-signaling is post-translationally extinguished by proteasom-dependent degradation (22) , we examined whether gemcitabineinduced MK upregulation occurs at the mRNA-level. Indeed, we found that MK mRNAexpression is dose-dependently induced by gemcitabine in chemoresistant PDAC cells (Fig.   2B, top) . In contrast, MK mRNA-levels in gemcitabine-treated chemosensitive cells remained either slightly decreased or unchanged (Fig. 2B, bottom) . Moreover, we investigated whether other chemotherapeutics used in PDAC treatment may also increase MK expression. As expected, treatment of chemoresistant cells with 5-Fluorouracil (5-FU) resulted in dosedependent MK upregulation, whereas no induction was again observed in chemosensitive cells ( Supplementary Fig. S1 ). Because MK is a secreted growth-factor involved in paracrine/autocrine regulation of growth and differentiation, we investigated whether the MKsecretion is increased in chemoresistant cells upon gemcitabine treatment. Indeed, we found robust and dose-dependently released MK protein-levels in gemcitabine-treated cells (Fig. 2C, top), whereas no increased MK-secretion was detectable in chemosensitive cells (Fig. 2C, 
bottom).
RNAi-mediated abrogation of MK induction by chemotherapy restores chemosensitivity. Because MK is induced at the mRNA and protein-level in gemcitabinetreated chemoresistant cells, we hypothesized that MK mediates intrinsic chemoresistance. Fig. S4 ). We then investigated whether MK is reexpressed in L3.6pl-Res cells and found tremendous MK mRNA as well as protein-levels compared to L3.6pl cells (Fig. 4B and C) . To pinpoint whether these molecular changes were due to changes in gene-expression, we quantified the expression of E-cadherin, Vimentin, Notch-2 and MK using real-time RT-PCR (Fig. 4C ). E-cadherin was greatly decreased whereas Vimentin, MK and Notch-2 expression was highly increased in L3.6pl-Res cells.
Interestingly, these results were independently confirmed by the expression data obtained for three chemoresistant PDAC cell lines (data not shown).
In proof-of-concept experiments, we depleted MK expression in L3.6pl-Res cells using two different siRNAs and treated cells with increasing gemcitabine-concentrations followed by viability assays. MK-depleted L3.6pl-Res cells showed substantially decreased chemoresistance and reached almost similar levels of chemosensitivity as L3.6pl cells whereas si-control transfections had no influence on chemoresistance (Fig. 4D) . We also It was previously shown that depletion of Notch-2 in EMT acquired cells induced the reversal to MET (15) . We therefore decreased Notch-2 expression in L3.6pl-Res cells using siRNA.
As shown in Figure 5 the applied MK and Notch-2 siRNAs were highly effective which resulted in decreased protein-expression compared to si-control ( Fig. 5A and B) . (Fig. 5C ). To further confirm that si-MK and/or siNotch-2 transfected cells are capable to induce MET, we analyzed Vimentin expression and found significantly decreased mRNA-levels (Fig. 5C) . Along with the mRNA-expression, we found elevated E-cadherin and dramatically decreased Vimentin protein-expression in siRNA-transfected L3.6pl-Res cells, which is consistent with the reversed transition from EMT to MET (Fig. 5A) 
expression in si-Notch-2 transfected cells suggesting that Notch downstream-signaling is affected (Fig. 5A) . Interestingly, we found decreased NF-κB protein-expression in si-MK transfected L3.6pl-Res cells suggesting that MK cross-talk with Notch to positively regulate Notch downstream-signaling (Fig. 5A) . It is well-known that an increased migration/invasion potential is a hallmark of mesenchymal cells. Therefore, we performed migration/invasion assay using MK-depleted PaCa 5061, 5072, 5156 and L3.6pl-Res cells or si-control transfected cells. As expected, we observed that MK-depleted chemoresistant PDAC cells migrated and invaded significantly lower than control-transfected cells in vitro ( Supplementary Fig. S5 ). (Fig. 6A, left) . Same experiment was done vice versa and revealed positive interaction between MK and Notch-2-exD (Fig. 6A, right) . ICD compared to untreated (control) cells, whereas full-length Notch-2 protein was slightly decreased (Fig. 6B) . We found that rh-MK-mediated cleavage of Notch-2 ICD was dose-independent and efficiently induced Notch-2 intracellular cleavage in the same manner. We then examined whether the rh-MK-mediated increase of Notch-2 ICD could force up NF-κB protein-expression which is known to be the central regulator of antiapoptotic pathways, and found elevated NF-κB protein-levels in Notch-2-activated cells. To further validate MK-mediated Notch-2 cleavage and activation, we analyzed proteinexpression of the well known Notch-target in mammals, Hes-1, and found elevated proteinlevels in rh-MK treated cells (Fig. 6B ).
MK mediates chemoresistance through binding and activation of
As it was recently shown that elevated Notch-1 expression is linked to increased resistance against oxaliplatin in colorectal cancer (16) 
Discussion
Despite improved diagnostic tools for PDAC, the often existing unspecific and indistinct symptoms delay diagnosis and render the majority of cases irresectable (25) . Also completely resected patients develop recurrent disease and eventually require palliative treatment. The majority of patients receive little or no benefit from adjuvant therapies mainly because most of the cancer cells have shown to be either intrinsically chemoresistant or become chemoresistant during therapy.
In this study we addressed the evident need of identifying novel players and to further comprehend their molecular role for chemoresistance in PDAC. It was recently shown that MK-secretion has cytoprotective functions in hepatocytes against cellular damage when exposed to heavy-metals or when the MK protein was applied to the location of ischemia 
upregulation suggesting a sine qua non in triggering and maintaining the EMT phenotype which is accompanied by increased chemoresistance. In proof-of-concept studies we found substantially increased chemosensitivity in Notch-2-depleted cells suggesting that Notchsignaling not only contributed to proliferation and differentiation but also to the regulation of cell-death through cross-talking with NF-κB-signaling. Our observations are therefore in agreement with previous studies showing Notch-signaling to positively influence NF-κB-signaling through the transcriptional regulation of positive regulators of the pathway in T-cell leukemia (31) . In this context it was shown that NF-κB is not only frequently constitutive active in PDAC but also represses E-cadherin expression in mammary epithelial cells and, thus, supporting EMT (32-33).
According to recent publications, the natural Notch ligand Jagged-1 is upregulated in chemoresistant PDAC (15) and chemoresistant colorectal cancer (16) . Obviously, downregulation of Jagged-1 expression in colorectal cancer revealed no functional relevance for chemoresistance (16) . Interestingly, we also observed that Jagged-1-depletion in PDAC unaltered. Therefore, we hypothesize that cells lacking corresponding signaling-cascades or a specific set of molecules are not capable to undergo EMT accompanied by increased chemoresistance in PDAC. Interestingly, it was already shown that MK and Notch-2 are independently involved in EMT processes. During early organogenesis in mice the MK expression was shown to be associated with epithelial-mesenchymal interactions. The authors observed that the MK gene was highly expressed in mesenchyme whereas the protein was distributed to the surface of epithelial cells which expressed non-detectable mRNA-amounts during several stages of tooth-development in mice suggesting that MK may act by a paracrine mechanism (34). Strikingly, it was shown that Notch-2 expression is also regulated by epithelial-mesenchymal interactions in the developing mouse tooth and is re-expressed in adults under pathological conditions suggesting that Notch-2 is involved in cellular repair processes during vertebrate development (35) .
Our data are also in full agreement with previous observations where MK was identified being overexpressed in chemoresistant gastric cancer cells (36) . Factors that may potentiate transcription or re-expression of MK are still unknown. Further, one could speculate that increased MK-secretion may also trigger intercellular chemoresistance by activating Notchsignaling in surrounding neighbouring cells in order to activate defense-mechanisms against drug-toxicity. Probably our results may also explain previous observations in which the treatment of chemosensitive cells with conditioned cell-culture media from MK overexpressed cells was linked to increased Akt-phosphorylation and, thus, increased cell viability (37).
In conclusion, our study revealed the identification of a novel mediator of EMT and drug- chemotherapy may force chemoresistant cells to revert to sensitive cells and, thus, may eventually be of tremendous benefit for patients suffering from advanced chemoresistant cancers, as it is unfortunately still the reality for PDAC.
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